CGT

654개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved654 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTCurated CoreFDAstaleNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
CGTCurated CoreFDAstaleIovance BiotherapeuticsApproved

lifileucel (Amtagvi, LN-144, tumor infiltrating lymphocyte)

Unresectable or metastatic melanoma after PD-1 blockade · Polyclonal tumor neoantigens (TIL)

#PolyclonaltumorneoantigensTIL#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved
CGTAAVCurated CoreFDAstaleNovartisApproved

onasemnogene abeparvovec (Zolgensma, AVXS-101, onasemnogene abeparvovec-xioi)

Spinal muscular atrophy (SMA) Type 1–3, pediatric · SMN1 (AAV9)

#SMN1AAV9#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 28Status Approved
CGTCurated CoreFDAstaleFerring PharmaceuticalsApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 10Status Approved
CGTCurated CoreFDAstaleVertexApproved

exagamglogene autotemcel (Casgevy, exa-cel, CTX001)

Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF

#BCL11AenhancerCRISPRCas9HbF#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 9Status Approved
CGTAAVCurated CoreFDAstaleBioMarinApproved

valoctocogene roxaparvovec (Roctavian, BMN 270, valoctocogene roxaparvovec-rvox)

Severe hemophilia A in adults · Factor VIII (AAV5)

#FactorVIIIAAV5#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 8Status Approved
CGTAAVCurated CoreFDAstaleCSL BehringApproved

etranacogene dezaparvovec (Hemgenix, AMT-061, CSL222, etranacogene dezaparvovec-drlb)

Hemophilia B (congenital Factor IX deficiency) in adults · Factor IX (AAV5 Padua)

#FactorIXAAV5Padua#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 7Status Approved
CGTAAVCurated CoreFDAstaleSpark TherapeuticsApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 7Status Approved
CGTCurated CoreFDAstalebluebird bioApproved

lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111)

Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)

#A-T87Q-globinlentiviral#CGT#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 2Status Approved
CGTLimited DatastaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 154Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTLimited DatastaleNeotropixPhase 1

biological agent (Seneca Valley Virus, Seneca Valley Virus (biological agent))

Carcinoid; Neuroendocrine · Carcinoid

#Carcinoid#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 93Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 92Status Recruiting
CGTLimited DatastaleAstraZenecaPhase 2

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Malignant Glioma; Glioblastoma · EGFR

#EGFR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 61Status Active
CGTLimited DatastaleNational Eye Institute (NEI)Phase 1

Higher (injection of scAAV2-P1ND4v2 1.0 X10e11vg, injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#Popular#cell-gene-therapy+3
Trials 61Status Active
CGTLimited DatastaleNational Eye Institute (NEI)Phase 1

injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low, injection of scAAV2-P1ND4v2 1.18x10e9 vg, injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),)

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 61Status Active
CGTLimited DatastaleNational Eye Institute (NEI)Phase 1

High (injection of scAAV2-P1ND4v2 2.4 X10e10vg, injection of scAAV2-P1ND4v2 2.4 X10e10vg (High))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 61Status Active
CGTLimited DatastaleNational Eye Institute (NEI)Phase 1

Med (injection of scAAV2-P1ND4v2 5.81 X10e9 vg, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med))

Leber's Hereditary Optic Neuropathy · Leber's Hereditary Optic Neuropathy

#LebersHereditaryOpticNeuropathy#CGT#Phase1#Popular#cell-gene-therapy+3
Trials 61Status Active
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting
CGTLimited DatastaleTransMolecularPhase 1

Chlorotoxin (EQ, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery))

Recurrent Glioblastoma; Recurrent Malignant Glioma · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 60Status Recruiting

1 / 33 pages

← PreviousNext →